ArticlePloS one2010
Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 127 citations in OpenAlex.
- Animal modelling with theMicrobiology (Reading, England) · 2025Article
- Lactate metabolism is exploited bymBio · 2025Article
- Genomic Repertoire of Twenty-Two Novel Vibrionaceae Species Isolated from Marine Sediments.Microbial ecology · 2025Article
- Virulence and genome analysis of three historicalFrontiers in cellular and infection microbiology · 2025Article
- Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets againstFrontiers in immunology · 2025Article
- Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.Microorganisms · 2024Review
- Review
- Mutation ofMicrobiology (Reading, England) · 2024Article
- Phenotypic and transcriptional characterization ofFrontiers in microbiology · 2024Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Preparation of a Klebsiella pneumoniae conjugate nanovaccine using glycol-engineered Escherichia coli.Microbial cell factories · 2023Article
- Why vary what's working? Phase variation and biofilm formation inFrontiers in microbiology · 2022Review
- Development of Immunoassays for Detection ofPathogens (Basel, Switzerland) · 2021Article
- Development, Phenotypic Characterization and Genomic Analysis of aFrontiers in microbiology · 2021Article
- Phase Variation of LPS and Capsule Is Responsible for Stochastic Biofilm Formation inFrontiers in cellular and infection microbiology · 2021Article
- Structural Studies of the Lipopolysaccharide Isolated fromInternational journal of molecular sciences · 2020Article
- The Francisella tularensis Polysaccharides: What Is the Real Capsule?Microbiology and molecular biology reviews : MMBR · 2020Review
- Formation of the Francisella tularensis Biofilm is Affected by Cell Surface Glycosylation, Growth Medium, and a Glucan Exopolysaccharide.Scientific reports · 2019Article
- Global Analysis of Genes Essential for Francisella tularensis Schu S4 GrowthJournal of bacteriology · 2019Article
- Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
Capsular polysaccharides are important factors in bacterial pathogenesis and have been the target of a number of successful vaccines. Francisella tularensis has been considered to express a capsular antigen but none has been isolated or characterized. We have developed a monoclonal antibody, 11B7, which recognizes the capsular polysaccharide of F. tularensis migrating on Western blot as a diffuse band between 100 kDa and 250 kDa. The capsule stains poorly on SDS-PAGE with silver stain but can be visualized using ProQ Emerald glycoprotein stain. The capsule appears to be highly conserved among strains of F. tularensis as antibody 11B7 bound to the capsule of 14 of 14 F. tularensis type A and B strains on Western blot. The capsular material can be isolated essentially free of LPS, is phenol and proteinase K resistant, ethanol precipitable and does not dissociate in sodium dodecyl sulfate. Immunoelectron microscopy with colloidal gold demonstrates 11B7 circumferentially staining the surface of F. tularensis which is typical of a polysaccharide capsule. Mass spectrometry, compositional analysis and NMR indicate that the capsule is composed of a polymer of the tetrasaccharide repeat, 4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-D-QuiNAc-(1->2)-beta-D-Qui4NFm-(1-, which is identical to the previously described F. tularensis O-antigen subunit. This indicates that the F. tularensis capsule can be classified as an O-antigen capsular polysaccharide. Our studies indicate that F. tularensis O-antigen glycosyltransferase mutants do not make a capsule. An F. tularensis acyltransferase and an O-antigen polymerase mutant had no evidence of an O-antigen but expressed a capsular antigen. Passive immunization of BALB/c mice with 75 microg of 11B7 protected against a 150 fold lethal challenge of F. tularensis LVS. Active immunization of BALB/c mice with 10 microg of capsule showed a similar level of protection. These studies demonstrate that F. tularensis produces an O-antigen capsule that may be the basis of a future vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.